Shuttle Pharma to Showcase Exciting Developments at VEGAS 2025
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) is gearing up to present at the much-anticipated Planet MicroCap Showcase: VEGAS 2025. This event, in collaboration with MicroCapClub, is set to take place in Las Vegas. On the afternoon of the event, Dr. Anatoly Dritschilo, the Chairman and Chief Scientific Officer, will unveil significant updates about the company’s innovations aimed at enhancing the lives of patients undergoing radiation therapy for cancer.
Focus of the Presentation
Dr. Dritschilo will delve into the company’s pivotal Phase 2 trial, which is examining the efficacy of Ropidoxuridine in conjunction with radiation therapy for patients battling glioblastoma. This specific focus underlines Shuttle Pharma's commitment to revolutionizing cancer treatment and improving patient outcomes.
Advancements in Shuttle Diagnostics
Furthermore, the presentation will shed light on Shuttle Pharma's subsidiary, Shuttle Diagnostics. This branch is making strides in developing groundbreaking diagnostic blood tests and imaging agents specifically for prostate cancer patients. These advancements are aimed at enhancing early detection and treatment precision, key components in the battle against cancer.
Event Details for Attendees
Those interested in witnessing this informative presentation can join on the scheduled date:
Date: Wednesday 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time)
The showcase will occur at Track 3 – Chablis, located at the prestigious Paris Hotel & Casino. Attendees will have the opportunity not only to learn from leading minds in the pharmaceutical industry but also to engage in valuable discussions following the presentation.
Opportunities for 1x1 Meetings
For those looking to explore deeper insights and personal interactions, Shuttle Pharma invites attendees to schedule 1x1 meetings with the management team. Interested parties can coordinate either through their Planet MicroCap representative or by reaching out to the investor relations team. These meetings are set to take place at the conference venue, allowing for in-person discussions about potential collaborations and insights into the company’s future directions.
About Shuttle Pharmaceuticals
Established in 2012 by a team of faculty members from Georgetown University Medical Center, Shuttle Pharmaceuticals is on a mission to enhance outcomes for cancer patients receiving radiation therapy. Their approach centers on refining the effectiveness of radiation treatment while minimizing its side effects. By harnessing the potential of radiation sensitizers, the company aims to boost cure rates, extend survival times, and elevate patients' quality of life.
Commitment to Innovation
Shuttle Pharma remains steadfast in its dedication to pioneering solutions that turn devastating diagnoses into manageable conditions. Through continuous research, they focus on integration with existing treatment methods like surgery, chemotherapy, and immunotherapy to offer patients comprehensive care. This holistic approach is integral to the development of their upcoming therapies.
Contact Information
For further inquiries or detailed information, contact Anatoly Dritschilo, M.D., at 240-403-4212 or via email at info@shuttlepharma.com. Investors can also reach out to Lytham Partners, LLC, and connect with Robert Blum at 602-889-9700 or through email at shph@lythampartners.com.
Frequently Asked Questions
What is Shuttle Pharmaceuticals focusing on at VEGAS 2025?
The focus will be on updates regarding their Phase 2 trial of Ropidoxuridine and radiation therapy for glioblastoma.
Who is presenting at the event?
Dr. Anatoly Dritschilo, the Chairman and Chief Scientific Officer, will be leading the presentation.
Where will the event take place?
The event is scheduled to be held at the Paris Hotel & Casino in Las Vegas.
How can I access the live presentation?
Details for accessing the live presentation will be provided at the event, and attendees can check for webcasting options online.
How can I schedule a meeting with the management team?
You can schedule a meeting through your Planet MicroCap representative or contact Shuttle Pharma’s investor relations team directly.
